
## Holly Peay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3857874/publications.pdf Version: 2024-02-01



Ηουν Ρελν

#	Article	lF	CITATIONS
1	Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria. AIDS and Behavior, 2022, 26, 1504-1516.	1.4	4
2	Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy. International Journal of Neonatal Screening, 2022, 8, 12.	1.2	6
3	Preparing newborn screening for the future: a collaborative stakeholder engagement exploring challenges and opportunities to modernizing the newborn screening system. BMC Pediatrics, 2022, 22, 90.	0.7	14
4	Caregivers' assessment of meaningful and relevant clinical outcome assessments for Sanfilippo syndrome. Journal of Patient-Reported Outcomes, 2022, 6, 40.	0.9	3
5	Parent Experiences of Sanfilippo Syndrome Impact and Unmet Treatment Needs: A Qualitative Assessment. Neurology and Therapy, 2021, 10, 197-212.	1.4	19
6	Patients' and caregivers' maximum acceptable risk of death for nonâ€curative gene therapy to treat Duchenne muscular dystrophy. Molecular Genetics & Genomic Medicine, 2021, 9, e1664.	0.6	7
7	Application of a framework to guide genetic testing communication across clinical indications. Genome Medicine, 2021, 13, 71.	3.6	14
8	Parent clinical trial priorities for fragile X syndrome: a best–worst scaling. European Journal of Human Genetics, 2021, 29, 1245-1251.	1.4	4
9	The Ethics of Predicting Autism Spectrum Disorder in Infancy. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 942-945.	0.3	6
10	Expert Evaluation of Strategies to Modernize Newborn Screening in the United States. JAMA Network Open, 2021, 4, e2140998.	2.8	23
11	Practical Considerations in Using Online Modified-Delphi Approaches to Engage Patients and Other Stakeholders in Clinical Practice Guideline Development. Patient, 2020, 13, 11-21.	1.1	62
12	"lf He Has it, We Know What to Do― Parent Perspectives on Familial Risk for Autism Spectrum Disorder. Journal of Pediatric Psychology, 2020, 45, 121-130.	1.1	14
13	Cohorts as collections of bodies and communities of persons: insights from the SEARCH010/RV254 research cohort. International Health, 2020, 12, 584-590.	0.8	6
14	Recommendations from Thai stakeholders about protecting HIV remission (â€~cure') trial participants: report from a participatory workshop. International Health, 2020, 12, 567-574.	0.8	4
15	Early Check: translational science at the intersection of public health and newborn screening. BMC Pediatrics, 2019, 19, 238.	0.7	26
16	How Biomedical HIV Prevention Trials Incorporate Behavioral and Social Sciences Research: A Typology of Approaches. AIDS and Behavior, 2019, 23, 2146-2154.	1.4	11
17	Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents. PLoS ONE, 2019, 14, e0213649.	1.1	21
18	Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best–worst scaling experiment in caregivers and adult patients. Orphanet Journal of Rare Diseases, 2019, 14, 102.	1.2	20

HOLLY PEAY

#	Article	IF	CITATIONS
19	Meaningful treatment outcomes for Sanfilippo syndrome: A study of caregiver preferences and prioritization. Molecular Genetics and Metabolism, 2019, 126, S112-S113.	0.5	2
20	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. Lancet HIV,the, 2019, 6, e259-e268.	2.1	139
21	Going off antiretroviral treatment in a closely monitored HIV "cure―trial: longitudinal assessments of acutely diagnosed trial participants and decliners. Journal of the International AIDS Society, 2019, 22, e25260.	1.2	23
22	Fragile X syndrome clinical trials: exploring parental decisionâ€making. Journal of Intellectual Disability Research, 2019, 63, 926-935.	1.2	10
23	Using an Online, Modified Delphi Approach to Engage Patients and Caregivers in Determining the Patient-Centeredness of Duchenne Muscular Dystrophy Care Considerations. Medical Decision Making, 2019, 39, 1019-1031.	1.2	22
24	The RAND/PPMD Patient-Centeredness Method: a novel online approach to engaging patients and their representatives in guideline development. European Journal for Person Centered Healthcare, 2019, 7, 470-475.	0.3	2
25	Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment. Journal of Medical Ethics, 2018, 44, medethics-2017-104433.	1.0	51
26	Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders. Clinical Trials, 2018, 15, 139-148.	0.7	30
27	An Evidenceâ€Based, Communityâ€Engaged Approach to Develop an Interactive Deliberation Tool for Pediatric Neuromuscular Trials. Journal of Genetic Counseling, 2018, 27, 416-425.	0.9	7
28	Psychosocial Needs and Facilitators of Mothers Caring for Children with Duchenne/Becker Muscular Dystrophy. Journal of Genetic Counseling, 2018, 27, 197-203.	0.9	6
29	Practical Considerations for Using Online Methods to Engage Patients in Guideline Development. Patient, 2018, 11, 155-166.	1.1	19
30	Patientâ€centered benefit–risk assessment in duchenne muscular dystrophy. Muscle and Nerve, 2017, 55, 626-634.	1.0	38
31	Engaging Patients and Caregivers Managing Rare Diseases to Improve the Methods of Clinical Guideline Development: A Research Protocol. JMIR Research Protocols, 2017, 6, e57.	0.5	15
32	"Watching time tick by…― Decision making for Duchenne muscular dystrophy trials. Contemporary Clinical Trials, 2016, 46, 1-6.	0.8	18
33	Prioritizing Parental Worry Associated with Duchenne Muscular Dystrophy Using Bestâ€Worst Scaling. Journal of Genetic Counseling, 2016, 25, 305-313.	0.9	31
34	Mothers' psychological adaptation to Duchenne/Becker muscular dystrophy. European Journal of Human Genetics, 2016, 24, 633-637.	1.4	31
35	What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. Journal of Virus Eradication, 2015, 1, 51-53.	0.3	34
36	Caregiver Preferences for Emerging Duchenne Muscular Dystrophy Treatments: A Comparison of Best-Worst Scaling and Conjoint Analysis. Patient, 2015, 8, 19-27.	1.1	44

HOLLY PEAY

#	Article	IF	CITATIONS
37	Measuring quality of life in muscular dystrophy. Neurology, 2015, 84, 1034-1042.	1.5	24
38	What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. Journal of Virus Eradication, 2015, 1, 51-53.	0.3	31
39	Recognition and management of motor delay and muscle weakness in children. American Family Physician, 2015, 91, 38-44.	0.1	8
40	Expectations and experiences of investigators and parents involved in a clinical trial for Duchenne/Becker muscular dystrophy. Clinical Trials, 2014, 11, 77-85.	0.7	36
41	A Community-Engaged Approach to Quantifying Caregiver Preferences for the Benefits and Risks of Emerging Therapies for Duchenne Muscular Dystrophy. Clinical Therapeutics, 2014, 36, 624-637.	1.1	96